Second-line dasatinib can be discontinued in patients with chronic myeloid leukaemia after they have sustained deep molecular response for more than 1 year, a study suggests. Writing in the Lancet Haematology the researchers said most haematologists think that patients should have achieved sustained deep molecular response for at least 2 years before imatinib treatment is ...
Dasatinib discontinuation after 1 Year possible in some CML patients
By Nicola Garrett
20 Nov 2015